Rezolute Stock Discussion

$Rezolute (RZLT.US)$ Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December
Benzinga· 5 mins ago
Rezolute, Inc. (NASDAQ:RZLT) on Wednesday announced the Independent Data Monitoring Committee's (DMC) recommendation to continue the Phase 3 sunRIZE study as planned in patients with congenital hyperinsulinism (HI) without increasing the study sample size.
HI is a genetic disorder in which the insulin cells of the pancreas, called beta cells, secr...

I've had a busy few weeks, man. Everyone got the 'rona here, and it was a bad one.
I'm cleaning my portfolio out a bit. Especially ones that don't seem to move on earnings.
My time horizon is off on some of these, too. Dont want to wait for clinical trials right now. Too exposed to dilution with those cats.
So far, I've cut
$Dell Technologies (DELL.US)$ : Never will appease, especially now with more costs.
$Intel (INTC.US)$ : They managed to get about 5B of their 8B owed from CHIPS, but with Tr...

$Rezolute (RZLT.US)$
will they be satisfied?

$Rezolute (RZLT.US)$ Reuters· 1 min ago
Rezolute Inc - DMC Reviewed Open-Label Arm for Infants, Target Drug Concentrations Safely Reached

$Rezolute (RZLT.US)$
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Tuesday, 4th February at 8:00 am
Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug concentrations were safely reached at tested doses
DMC approved enrollment of infants into the double-blind portion of the study
sunRIZE enrollment completion expected in Q2 2025...

$Rezolute (RZLT.US)$
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Tuesday, 7th January at 8:00 am
Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism (HI)
Ersodetug continues to advance in clinical development as a potential treatment for hypoglycemia caused by all forms of hyperinsulinism; t...

second trade of the day. small but good!
$Rezolute (RZLT.US)$

Here have some gifts, my weekend work so far:
$Yalla (YALA.US)$ diversity outside Asia/us, expanding reach
$NexGel (NXGL.US)$ specialized medical applications will see higher demand as the saline shortage goes on, and more look to alternatives
$Lumen Technologies (LUMN.US)$ ongoing transitions, personally see an increase in presence (which is impressive, honestly, I'm a nobody in random town), and they are approaching good buy levels
$Rezolute (RZLT.US)$ also approaching oversold
$Ventyx Biosciences (VTYX.US)$ impressiv...

$Rezolute (RZLT.US)$
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
Rezolute, Inc. (Nasdaq: RZLT) announced that the FDA has lifted partial clinical holds on RZ358 (ersodetug), their potential treatment for hypoglycemia caused by congenital hyperinsulinism (HI). This allows the company to include U.S. participants in their ongoing global Phase 3 sunRIZE study. Rezolute plans to begin U.S. enrollm...

$Rezolute (RZLT.US)$ Reuters· 1 min ago
FDA Lifts Partial Clinical Holds on Rz358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study